California Public Employees Retirement System Affimed N.V. Transaction History

California Public Employees Retirement System

$141 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$7.78 - $11.4 $1.29 Million - $1.89 Million	-165,400 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$5.12 - $8.48 $82,140 - $136,044	-16,043 Reduced 8.84%	165,400 $1.31 Million
Q4 2020 Feb 02, 2021	SELL	$3.16 - $7.03 $4,477 - $9,961	-1,417 Reduced 0.77%	181,443 $1.06 Million
Q3 2020 Nov 05, 2020	BUY	$3.26 - $4.73 $66,504 - $96,492	20,400 Added 12.56%	182,860 $620,000
Q2 2020 Aug 12, 2020	BUY	$1.58 - $4.63 $19,844 - $58,152	12,560 Added 8.38%	162,460 $750,000
Q1 2020 May 12, 2020	SELL	$1.44 - $3.02 $23,328 - $48,924	-16,200 Reduced 9.75%	149,900 $237,000
Q4 2019 Jan 27, 2020	SELL	$2.25 - $3.07 $42,750 - $58,330	-19,000 Reduced 10.26%	166,100 $455,000
Q3 2019 Oct 31, 2019	BUY	$2.67 - $3.65 $26,967 - $36,865	10,100 Added 5.77%	185,100 $544,000
Q3 2017 Nov 15, 2017	BUY	$1.95 - $2.25 $341,250 - $393,750	175,000	175,000 $394,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account